{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:51:49Z","timestamp":1762332709554,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020473","name":"Ministry of Research Technology and Higher Education of the Republic of Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010447","name":"Kementerian Riset, Teknologi dan Pendidikan Tinggi","doi-asserted-by":"publisher","award":["PL\/2023","122\/E5\/PG.02.00","3175\/UN1\/DITLIT\/DitLit\/PT.01.03\/2023","0536\/E5\/PG.02.00\/2023"],"award-info":[{"award-number":["PL\/2023","122\/E5\/PG.02.00","3175\/UN1\/DITLIT\/DitLit\/PT.01.03\/2023","0536\/E5\/PG.02.00\/2023"]}],"id":[{"id":"10.13039\/501100010447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vhri.2025.101147","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:34:56Z","timestamp":1749141296000},"page":"101147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Utility Analysis of Expanding Human Papillomavirus Vaccination to Adult Women in Indonesia: A Markov Model Approach"],"prefix":"10.1016","volume":"50","author":[{"given":"Nur Rochmah","family":"Hidayati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwi","family":"Endarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didik","family":"Setiawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vhri.2025.101147_bib1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"De Martel","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"3","key":"10.1016\/j.vhri.2025.101147_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"author":"Bruni","key":"10.1016\/j.vhri.2025.101147_bib3"},{"year":"2021","series-title":"Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07\/Menkes\/6779\/2021 tentang Program Introduksi Imunisasi Human Papillomavirus Vaccine (HPV) Tahun 2022-2024","key":"10.1016\/j.vhri.2025.101147_bib6"},{"key":"10.1016\/j.vhri.2025.101147_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med"},{"issue":"12","key":"10.1016\/j.vhri.2025.101147_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3390\/vaccines9121413","article-title":"Human papillomavirus vaccine efficacy and effectiveness against cancer","volume":"9","author":"Kamolratanakul","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.vhri.2025.101147_bib9","first-page":"265","article-title":"Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis","volume":"47","author":"Setiawan","year":"2017","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.vhri.2025.101147_bib10","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.vhri.2025.101147_bib11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vhri.2025.101147_bib12","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/ijc.31231","article-title":"Vaccination protects against invasive HPV-associated cancers","volume":"142","author":"Luostarinen","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vhri.2025.101147_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1052324","article-title":"Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: a meta-analysis","volume":"13","author":"Ren","year":"2022","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.vhri.2025.101147_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.adaj.2019.10.010","article-title":"Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines","volume":"151","author":"Villa","year":"2020","journal-title":"J Am Dent Assoc"},{"issue":"11","key":"10.1016\/j.vhri.2025.101147_bib15","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/cncr.29111","article-title":"A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer: male HPV vaccination for OPC prevention","volume":"121","author":"Graham","year":"2015","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2025.101147_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2127983","article-title":"Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain","volume":"18","author":"Linertov\u00e1","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vhri.2025.101147_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.628434","article-title":"Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent human papillomavirus vaccine in Belgium","volume":"12","author":"Simoens","year":"2021","journal-title":"Front Pharmacol"},{"issue":"34","key":"10.1016\/j.vhri.2025.101147_bib18","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1016\/j.vaccine.2018.07.018","article-title":"Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour","volume":"36","author":"Wolff","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vhri.2025.101147_bib19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/infdis\/jix476","article-title":"The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation","volume":"216","author":"Drolet","year":"2017","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vhri.2025.101147_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/infdis\/jiu413","article-title":"Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway","volume":"211","author":"Burger","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vhri.2025.101147_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12885-016-2207-3","article-title":"Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.vhri.2025.101147_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12879-020-05632-0","article-title":"Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study","volume":"21","author":"Cody","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1016\/j.vhri.2025.101147_bib23","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/21645515.2020.1852870","article-title":"Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States","volume":"17","author":"Daniels","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vhri.2025.101147_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vhri.2015.10.010","article-title":"Cost-utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia","volume":"9","author":"Setiawan","year":"2016","journal-title":"Value Health Reg Issues"},{"issue":"19","key":"10.1016\/j.vhri.2025.101147_bib48","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"issue":"9686","key":"10.1016\/j.vhri.2025.101147_bib49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.vhri.2025.101147_bib28","doi-asserted-by":"crossref","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"De Sanjos\u00e9","year":"2018","journal-title":"JNCI Cancer Spectr"},{"issue":"12","key":"10.1016\/j.vhri.2025.101147_bib29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","article-title":"HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis","volume":"15","author":"Ndiaye","year":"2014","journal-title":"Lancet Oncol"},{"year":"2023","series-title":"Kebijakan imunisasi antigen baru di Indonesia.Pdf","author":"Direktorat Pengelolaan Imunisasi Kementerian Kesehatan","key":"10.1016\/j.vhri.2025.101147_bib30"},{"issue":"S1","key":"10.1016\/j.vhri.2025.101147_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S0020-7292(06)60030-1","article-title":"Carcinoma of the cervix uteri: FIGO 26th Annual Report on the results of treatment in gynecological cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynecol Obstet"},{"year":"2023","series-title":"Vulvar Cancer NCCN Clinical Practice Guidelines in Oncology","key":"10.1016\/j.vhri.2025.101147_bib32"},{"issue":"5","key":"10.1016\/j.vhri.2025.101147_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197098","article-title":"Quality of life of the Indonesian general population: test-retest reliability and population norms of the EQ-5D-5L and WHOQOL-bref","volume":"13","author":"Purba","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vhri.2025.101147_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/sextrans-2011-050161","article-title":"Quality of life valuations of HPV-associated cancer health states by the general population","volume":"88","author":"Conway","year":"2012","journal-title":"Sex Transm Infect"},{"issue":"3","key":"10.1016\/j.vhri.2025.101147_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230359","article-title":"Cervical cancer prevention in Indonesia: an updated clinical impact, cost-effectiveness and budget impact analysis","volume":"15","author":"Setiawan","year":"2020","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vhri.2025.101147_bib42","first-page":"2011","article-title":"The cost-effectiveness of quadrivalent human papillomavirus vaccination in Indonesia","volume":"18","author":"Kosen","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.vhri.2025.101147_bib43","series-title":"Cost-Effectiveness of a HPV-Vaccination Catch-Up Program for Females 26 Years or Younger in a Norwegian Setting","first-page":"91","author":"Jim\u00e9nez","year":"2014"},{"issue":"1","key":"10.1016\/j.vhri.2025.101147_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1186\/s12913-016-1662-5","article-title":"The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach","volume":"16","author":"Chanthavilay","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"37","key":"10.1016\/j.vhri.2025.101147_bib45","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1016\/j.vaccine.2013.06.008","article-title":"Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium","volume":"31","author":"Demarteau","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vhri.2025.101147_bib46","doi-asserted-by":"crossref","first-page":"22","DOI":"10.7326\/M19-1182","article-title":"Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States","volume":"172","author":"Laprise","year":"2020","journal-title":"Ann Intern Med"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992500072X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210992500072X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:47:12Z","timestamp":1762332432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210992500072X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"alternative-id":["S221210992500072X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101147","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Expanding Human Papillomavirus Vaccination to Adult Women in Indonesia: A Markov Model Approach","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101147"}}